Page 94 - 南京医科大学自然版
P. 94
第44卷第4期
·532 · 南 京 医 科 大 学 学 报 2024年4月
(续表1)
Phase of
Item Pancreatic Route of drug
Period Institution Intervention clinical
number cancer category administration
trial
2
10 2018.11-2021.10 Wayne State Metastatic pancreatic CPI ⁃ 613:500 mg/m(D1,D3); Intravenous Ⅲ
2
University,USA cancer(Ⅳ) Oxaliplatin:65 mg/m(2 weeks), injection
Irinotecan:120 mg/m(2 weeks);
2
2
5⁃Fu:400 mg/m(2 weeks);Cal⁃
cium folinat:400 mg/m(2 weeks)
2
11 2019.01-2021.01 British Columbia Pancreatic cancer Metformin:500 mg/m 2 Oral Ⅱ
Cancer Agency,UK ECOG 0⁃2 (2 times/d)
12 2021.02-2022.01 Washington University PDAC,PSCC,later Dapagliflozin:5mg/d(≤2 weeks), Oral Ⅰ
School of Medicine, periodormetastasis of 10 mg/d( > 2 & < 8 weeks)
USA pancreatic cancer
13 2021.06-2023.03 Oxford University, Unresectable or meta⁃ ThermoDox:50 mg/m 2 Intravenous
Ⅰ
UK static pancreatic can⁃ injection
cer(Ⅳ)
14 2023.03-2030.03 Northwestern Pancreatic cancer CPI⁃613:500 mg/m 2 Intravenous Ⅱ
University,USA ECOG ≤1 (≤4 weeks),2 times dose injection
increased( > 4 th weeks);5⁃Fu:
2
400 mg/m (2 weeks)or Gem⁃
citabine:1 000 mg/m(8 d)
2
15 2023.10-2027.03 HangzhouFirst Unresectable or Gemcitabine:1 000 mg/m 2 Intravenous Ⅰ
People’s Hospital, metastatic (8 d);Kagliflozin: injection and
2
China pancreatic cancer 400 mg/(m ·d) oral
[参考文献] creatic cancer[J]. Cell Death Dis,2024,15(2):131
[7] XU L,MA X,ZHANG X,et al. Hsa⁃circ_0007919 induces
[1] SIEGEL R L,MILLER K D,WAGLE N S,et al. Cancer
LIG1 transcription by binding to FOXA1/TET1 to en⁃
statistics,2023[J]. CA Cancer J Clin,2023,73(1):17-
hance the DNA damage response and promote gemcitabi⁃
48
ne resistance in pancreatic ductal adenxarcinomo[J]. Mol
[2] SARVEPALLI D,RASHID M U,RAHMAN A U,et al.
Cancer,2023,22(1):195
Gemcitabine:a review of chemoresistance in pancreatic
[8] DEBERARDINIS R J,CHANDEL N S. Fundamentals of
cancer[J]. Crit Rev Oncog,2019,24(2):199-212
cancer metabolism[J]. Sci Adv,2016,2(5):e1600200
[3] SPRINGFELD C,JÄGER D,BÜCHLER M W,et al. Che⁃
[9] LI Z Y,ZHANG H F. Reprogramming of glucose,fatty acid
motherapy for pancreatic cancer[J]. Presse Med,2019,48
and amino acid metabolism for cancer progression[J].
(3 Pt 2):159-174 Cell Mol Life Sci,2016,73(2):377-392
[4] CHIOREAN E G,COVELER A L. Pancreatic cancer:op⁃ [10]CAO Y H. Adipocyte and lipid metabolism in cancer drug
timizing treatment options,new,and emerging targeted resistance[J]. J Clin Invest,2019,129(8):3006-3017
therapies[J]. Drug Des Devel Ther,2015,9:3529-3545 [11]CHANDEL N S. Carbohydrate metabolism[J]. Cold Spring
[5] ONO H,MURASE Y,YAMASHITA H,et al. RRMI is Harb Perspect Biol,2021,13(1):a040568
mediated by histone acetylation through gemcitabine re⁃ [12]NEUFELD E F,GINSBURG V. Carbohydrate metabo⁃
sistance and contributes to invasiveness and ECM remo⁃ lism[J]. Annu Rev Biochem,1965,34:297-312
deling in pancrentic cancer[J]. Int J Oncol,2023,62(4):51 [13]AVOLIO R,MATASSA D S,CRISCUOLO D,et al. Modu⁃
[6] DASH S,UEDA T,KOMURO A,et al. Deoxycytidine ki⁃ lation of mitochondrial metabolic reprogramming and oxi⁃
nase inactivation enhances gemcitabine resistance and dative stress to overcome chemoresistance in cancer[J].
sensitizes mitochondrial metabolism interference in pan⁃ Biomolecules,2020,10(1):135